Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.
Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was approved by Health Canada in September 2020. Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.
Talazoparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. This indication is approved by the FDA, EMA, and Health Canada.
In the US, talazoparib is also indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Marin Cancer Care, Inc., Greenbrae, California, United States
UCLA Hematology-Oncology, Santa Monica, California, United States
Stanford Cancer Institute, Stanford, California, United States
University of California Los Angeles, Los Angeles, California, United States
Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
UCLA Hematology/Oncology, Los Angeles, California, United States
Santa Monica - UCLA Medical Center & Orthopaedic Hospital, Santa Monica, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.